Amicus Therapeutics, Inc.
FOLD
Rank in Stocks
#3695
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Share Price
$14.49
Last synced: 2026-04-27
Market Cap
$4.55B
Change (1 day)
0.00%
Change (1 year)
80.22%
Country
US
Trade Amicus Therapeutics, Inc. (FOLD)
Category
Healthcare
Number of shares outstanding for Amicus Therapeutics, Inc. (FOLD)
Number of shares outstanding as of December 2025: 309.03M
According to Amicus Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 309.03M. At the end of December 2023 the company had 295.16M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Amicus Therapeutics, Inc. (FOLD) from 2003 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 309.03M | 1.53% |
| 2024 | 304.38M | 3.12% |
| 2023 | 295.16M | 2.11% |
| 2022 | 289.06M | 6.50% |
| 2021 | 271.42M | 4.85% |
| 2020 | 258.87M | 7.67% |
| 2019 | 240.42M | 29.40% |
| 2018 | 185.79M | 21.15% |
| 2017 | 153.36M | 14.10% |
| 2016 | 134.40M | 22.27% |
| 2015 | 109.92M | 47.66% |
| 2014 | 74.44M | 45.15% |
| 2013 | 51.29M | 12.56% |
| 2012 | 45.57M | 31.81% |
| 2011 | 34.57M | 24.64% |
| 2010 | 27.73M | 22.59% |
| 2009 | 22.62M | 0.58% |
| 2008 | 22.49M | 69.95% |
| 2007 | 13.24M | 1,698.42% |
| 2006 | 735.97K | 79.41% |
| 2005 | 410.22K | 33.39% |
| 2004 | 307.54K | 0.00% |
| 2003 | 307.54K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -17.84% |
US
|
|
| 396.00M | 28.14% |
US
|
|
| 478.91M | 54.97% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -79.88% |
NL
|
